Apply for Grants

The Division of Cancer Treatment and Diagnosis funds a large portfolio of grants and contracts. Here we provide a listing of funding opportunities that are accepting applications. Please visit this page regularly, as new funding opportunities are added upon approval by NCI.

Important DCTD Grantsmanship Resources

Awaiting Receipt of Applications (ARAs) for Large Budget Grant Applications

Program Project (P01) Grant Development Guidance for Investigators Interested in DCTD Research Areas

Funding Opportunities through DCTD’s Programs

Visit the websites of DCTD's individual programs for more information on available funding opportunities.

Additional DCTD Funding Opportunity Announcements (FOAs)
(listed by expiration date)
Title	Announcement Number	Expiration Date	Activity Code
Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)	PAR-20-313; PAR-20-314	October 11, 2023	UH2/H3
Revision Applications for Validation of Biomarker Assays Developed Through NIH-Supported Research Grants (Clinical Trial Not Allowed)	PAR-23-088	October 28, 2023	R01
Mechanisms of Fusion-Driven Oncogenesis in Childhood Cancers (Clinical Trial Not Allowed)	RFA-CA-23-036	November 16, 2023	U01
Next Generation Chemistry Centers for Fusion Oncoproteins (Clinical Trial Not Allowed)	RFA-CA-23-037	November 16, 2023	UM1
Targeted Fusion Oncoproteins in Childhood Cancers Network Pre-Application Webinar for RFA-CA-23-036 and RFA-CA-23-037
National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required)	PAR-21-033	January 8, 2024	R01
Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (Clinical Trial Not Allowed)	PAR-21-166	January 8, 2024	R01
Exploratory/Developmental Bioengineering Research Grants (EBRG) (Clinical Trial Not Allowed)	PAR-22-090	January 8, 2025	R21
Exploratory/Developmental Bioengineering Research Grants (EBRG) (Clinical Trial Optional)	PAR-22-091	January 8, 2025	R21
Bioengineering Partnerships with Industry (U01 Clinical Trial Optional)	PAR-22-123	January 8, 2025	U01
Administrative Supplements to Support Cancer Disparity Collaborative Research (Clinical Trial Optional)	PAR-22-114	January 24, 2025	Admin Suppl
Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research (R01 Clinical Trial Optional)	PAR-22-099	May 8, 2025	R01
Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (Clinical Trial Not Allowed)	PAR-22-086	May 8, 2025	R21
Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (Clinical Trial Not Allowed)	PAR-22-085	May 8, 2025	R01
Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE) (Clinical Trial Not Allowed)	PAR-22-139	May 8, 2025	R01
Systematic Testing of Radionuclides in Preclinical Experiments (Clinical Trial Not Allowed)	PAR-22-140	May 8, 2025	R21
NCI Clinical and Translational Exploratory/Developmental Studies (Clinical Trial Optional)	PAR-22-216	July 2, 2025	R21
Imaging, biomarkers and digital pathomics for the early detection of premetastatic cancer and precancerous lesions associated with lethal phenotypes (Clinical Trial Optional)	PAR-22-131	September 8, 2025	R01
Bioengineering Research Grants (Clinical Trial Optional)	PAR-22-243	September 8, 2025	R01
Bioengineering Research Grants (Clinical Trial Not Allowed)	PAR-22-242	September 8, 2025	R01
Coinfection and Cancer (Clinical Trial Not Allowed)	PAR-23-056	November 17, 2025	R21
Innovative Research in Cancer Nanotechnology (IRCN; Clinical Trial Not Allowed)	PAR-23-246	May 5, 2026	R01
Assay Development and Screening for Discovery of Chemical Probes, Drugs or Immunomodulators (Clinical Trial Not Allowed)	PAR-23-264	September 8, 2026	R01
Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems (Clinical Trials Optional)	PAR-23-259	January 8, 2027	R01